Literature DB >> 12952254

BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia.

S Veeraraghavan1, P I Latsi, A U Wells, P Pantelidis, A G Nicholson, T V Colby, P L Haslam, E A Renzoni, R M du Bois.   

Abstract

Idiopathic pulmonary fibrosis (IPF), which has the histological pattern of usual interstitial pneumonia (UIP), is a progressive interstitial lung disease with a poor prognosis. Idiopathic interstitial pneumonias with a histological pattern of nonspecific interstitial pneumonia (NSIP) have a better prognosis than UIP, and may present with a clinical picture identical to IPF. The authors hypothesised that bronchoalveolar lavage (BAL) findings may distinguish between UIP and NSIP, and have prognostic value within disease subgroups. BAL findings were studied retrospectively in 54 patients with histologically proven (surgical biopsy) idiopathic UIP (n=35) or fibrotic NSIP (n=19), all presenting clinically as IPF. These findings were also compared with the BAL profile of patients with other categories of idiopathic interstitial pneumonias. BAL total and differential cell counts did not differ between the two groups. Survival was better in NSIP. In neither group were BAL findings predictive of survival or changes in lung function at 1 yr, even after adjustment for disease severity, smoking and treatment. BAL differential counts in fibrotic NSIP differed from respiratory bronchiolitis-associated interstitial lung disease, but not from desquamative interstitial pneumonia or cellular NSIP. The authors conclude that bronchoalveolar lavage findings do not discriminate between usual interstitial pneumonia and nonspecific interstitial pneumonia in patients presenting with clinical features of idiopathic pulmonary fibrosis, and have no prognostic value, once the distinction between the two has been made histologically.

Entities:  

Mesh:

Year:  2003        PMID: 12952254     DOI: 10.1183/09031936.03.00105202

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  23 in total

1.  Non-specific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders.

Authors:  Toshio Sato; Jiro Fujita; Ichiro Yamadori; Yuji Ohtsuki; Takeo Yoshinouchi; Shuji Bandoh; Michiaki Tokuda; Toshihiko Ishida
Journal:  Rheumatol Int       Date:  2005-11-08       Impact factor: 2.631

Review 2.  Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study.

Authors:  Kristin B Highland; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

3.  Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis?

Authors:  Elena Bargagli; Carmela Olivieri; Marcella Cintorino; Rosa M Refini; Nicola Bianchi; Antje Prasse; Paola Rottoli
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

Review 4.  Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology.

Authors:  Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi
Journal:  Curr Rheumatol Rev       Date:  2019

Review 5.  Interstitial lung disease: the diagnostic role of bronchoscopy.

Authors:  Jad Kebbe; Tony Abdo
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Fernando J Martinez; Lyrica X Liu; Susan Murray; Meilan K Han; Ella A Kazerooni; Barry H Gross; Jeffrey Myers; William D Travis; Thomas V Colby; Galen B Toews; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2010-01-07       Impact factor: 21.405

Review 7.  Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment.

Authors:  Nasreen Khalil; Robert O'Connor
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

8.  Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis.

Authors:  Thomas H Sisson; Michael Mendez; Karen Choi; Natalya Subbotina; Anthony Courey; Andrew Cunningham; Aditi Dave; John F Engelhardt; Xiaoming Liu; Eric S White; Victor J Thannickal; Bethany B Moore; Paul J Christensen; Richard H Simon
Journal:  Am J Respir Crit Care Med       Date:  2009-10-22       Impact factor: 21.405

Review 9.  Challenges in pulmonary fibrosis . 4: smoking-induced diffuse interstitial lung diseases.

Authors:  Athol U Wells; Andrew G Nicholson; David M Hansell
Journal:  Thorax       Date:  2007-10       Impact factor: 9.139

10.  Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.

Authors:  Charlie Strange; Marcy B Bolster; Michael D Roth; Richard M Silver; Arthur Theodore; Jonathan Goldin; Philip Clements; Joanie Chung; Robert M Elashoff; Robert Suh; Edwin A Smith; Daniel E Furst; Donald P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.